Arrivent Biopharma licenses ex-China rights to Lepu’s ADC for gastrointestinal cancers
Jan. 22, 2025
Arrivent Biopharma Inc. has entered into an exclusive license agreement with Lepu Biopharma Co. Ltd. for MRG-007, an antibody-drug conjugate (ADC) in development for gastrointestinal cancers.